Advertisement

Myeloid Malignancies

  • Laurent Plawny
Chapter

Abstract

Myeloid malignancies comprise the various myeloid proliferative stem cell disorders. In this chapter, the side effects of the currently used drugs are given as used in the general hematologic clinic. For the various disorders covered, the side effects of the medications are pleomorphic; therefore, for the tyrosine kinase inhibitors in chronic myeloid leukemia, a tabulated summary is given. Hematopoietic stem cells, autologous as well as allogeneic, are not covered. These treatment modalities are used in very specialized units, and the patient’s follow-up during the first few months is also done through these units, which are very familiar with the therapies.

Keywords

Myelodysplastic syndromes Acute myeloid leukemia Polycythemia vera Essential thrombocythemia Chronic myeloid leukemia 

References

  1. 1.
    Chabner B, Wilson W, Supko J. Pharmacology and toxicity of antineoplastic drugs. In:Williams haematology. 7th ed. New York: McGraw-Hill; 2006. p. 249–74.Google Scholar
  2. 2.
    Fernandez H. New trends in the standard of care for initial therapy. Hematology Am Soc Hematol Educ Program. 2010;2010:56–61.PubMedGoogle Scholar
  3. 3.
    Fenaux P, Gattermann N, Seymour JF, Hellström-Lindberg E, Mufti GJ, Duehrsen U, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol. 2010;149(2):244–9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LR, List A, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2010;85(2):130–8.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Almeida AM, Pierdomenico F. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: effective management with concomitant prednisolone. Leuk Res. 2012;36(9):e211–3.CrossRefPubMedGoogle Scholar
  6. 6.
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–32.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–7.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer. 1981;48(12):2577–82.CrossRefPubMedGoogle Scholar
  9. 9.
    Johnson H, Smith TJ, Desforges J. Cytosine-arabinoside-induced colitis and peritonitis: nonoperative management. J Clin Oncol. 1985;3(5):607–12.CrossRefPubMedGoogle Scholar
  10. 10.
    Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027–36.CrossRefPubMedGoogle Scholar
  11. 11.
    Mandelli F, Vignetti M, Suciu S, Stasi R, Stasi R, Petti MC, Meloni G, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27(32):5397–403.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Moreb JS, Oblon DJ. Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer. 1992;70:2637.CrossRefPubMedGoogle Scholar
  13. 13.
    Leoni F, Ciolli S, Nozzoli C, Marrani C, Caporale R, Ferrini PR. Idarubicin in induction treatment of acute myeloid leukemia in the elderly. Haematologica. 1997;82(5 Suppl):13–8.PubMedGoogle Scholar
  14. 14.
    Legha SS, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. Blood. 1982;60(2):484–90.PubMedGoogle Scholar
  15. 15.
    Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. J Clin Oncol. 2012;30(20):2492–9.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Claxton D, Erba HP, Faderl S, Arellano M, Lyons RM, Kovacsovics T, et al. Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leuk Lymphoma. 2012;53(3):435–40.CrossRefPubMedGoogle Scholar
  17. 17.
    Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010;28(4):549–55.CrossRefPubMedGoogle Scholar
  18. 18.
    Candoni A, Martinelli G, Toffoletti E, Chiarvesio A, Tiribelli M, Malagola M, et al. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk Res. 2008;32(12):1800–8.CrossRefPubMedGoogle Scholar
  19. 19.
    de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008;22(2):258–64.CrossRefPubMedGoogle Scholar
  20. 20.
    Baz W, Najfeld V, Yotsuya M, Talwar J, Terjanian T, Forte F. Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia. Clin Med Insights Oncol. 2012;6:149–52.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am J Hematol. 2012;87(5):552–4.  https://doi.org/10.1002/ajh.23160.CrossRefPubMedGoogle Scholar
  22. 22.
    Kluger N, Naud M, Françès P. Toenails melanonychia induced by hydroxyurea. Presse Med. 2012;41(4):444–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Gugliotta L, Tieghi A, Tortorella G, Scalzulli PR, Ciancia R, Lunghi M, et al. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res. 2011;35(12):1557–63.CrossRefPubMedGoogle Scholar
  24. 24.
    Birgegård G, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica. 2004;89(5):520–7.PubMedGoogle Scholar
  25. 25.
    Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H, COMFORT-II Investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–53.CrossRefPubMedGoogle Scholar
  29. 29.
    Kirito K, Sakamoto M, Enomoto N. Elevation of the hepatitis B virus DNA during the treatment of polycythemia vera with the JAK kinase inhibitor ruxolitinib. Intern Med. 2016;55(10):1341–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of HematologyCentre Hospitalier de LuxembourgLuxembourgLuxembourg

Personalised recommendations